Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

RCT (n=105) reports empagliflozin significantly reduced left ventricular (LV) end-systolic volume index by 6.0 mL/m2 (95% CI, –10.8 to –1.2, p=0.015) vs. placebo; and favourable reverse LV remodelling may reduce heart failure hospitalisation and mortality in these patients.

Source:

Circulation